Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04457934
Other study ID # 001
Secondary ID 125
Status Recruiting
Phase
First received
Last updated
Start date September 2020
Est. completion date August 2021

Study information

Verified date September 2020
Source Johannes Gutenberg University Mainz
Contact Helmut Neumann, Prof.
Phone +491786651595
Email helmut.neumann@unimedizin-mainz.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients presenting for endoscopic surveillance of IBD or colorectal screening colonoscopy at one of the participating centers will be asked to participate in the present study after careful evaluation of inclusion and exclusion criteria. The aim is that the final study population will comprise of 50% IBD patients and 50% colorectal cancer screening patients. Before inclusion, all patients have to sign the written informed consent. All participating patients will receive PLENVU, a well-known and approved bowel preparation agent. Bowel preparation is performed following the general recommendations of use. Following the bowel preparation, patients are asked if they have well tolerated the preparation, if they already had a colonoscopy in the past with another bowel preparation agent and if they would prefer PLENVU or another bowel preparation for their next endoscopy examination. Endoscopy is performed in standard way and effectiveness of the bowel preparation is specifically highlighted by the physician on the documentation report. Finally, data is analyzed regarding effectiveness of PLENVU for bowel preparation and patient satisfaction.


Description:

PLENVU is effective for bowel preparation and the efficacy and safety of PLENVU has been investigated in randomized controlled trials in patients undergoing gut cleansing prior to colonoscopy. Data on the specific screening population and for patients suffering from IBD however is limited to date. The aim of the current study is to fill this gap and to provide data of the effectiveness of PLENVU for the specific patients groups in order to provide specific recommendations for an adequate bowel preparation in those groups.

In general, bowel-preparation in IBD patients is often more challenging. This might be due to the chronic disease burden but also according to compliance factors of individual patients. Of note, an adequate bowel-preparation is of paramount importance in IBD in order to detect subtle neoplasia and to perform chromoendoscopy, which is still recommended by the updated ESGE guideline.

It is anticipated, that PLENVU will help IBD patients to achieve a better bowel preparation, thereby yielding in more effective screening colonoscopies and higher acceptance rates of patients for surveillance colonoscopies. In order to show that no significant differences are seen in the included IBD cohort compared to the general screening population (bias risk), the investigators aim to also include patients from the normal screening population.


Recruitment information / eligibility

Status Recruiting
Enrollment 290
Est. completion date August 2021
Est. primary completion date January 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- • Suspicion or history of IBD

- Screening colonoscopy

- Indication for colonoscopy

- Age 18-75 years

- Written informed consent

Exclusion Criteria:

- • Pregnancy or lactating

- Lower gastrointestinal bleeding with hemodynamic instability

- Bowel obstruction

- ASA >3

- Not sufficiently corrected anticoagulation disorders

- Plenvu must not be taken:

- if you are allergic (hypersensitive) to the active ingredients or any of the other ingredients of this medicine;

- if you have a blockage (obstruction) in the digestive tract.

- if you have a breakthrough (perforation) in the wall of the digestive tract;

- if you suffer from intestinal obstruction (Ileus);

- if you suffer from a disturbance of gastric emptying (e.g. gastroparesis, gastric retention);

- if you suffer from phenylketonuria. Phenylketonuria is a congenital metabolic disease in which phenylalanine cannot be processed by your body. Plenvu contains aspartame as a source of phenylalanine;

- if you suffer from glucose-6-phosphate dehydrogenase deficiency;

- if you suffer from acute colon enlargement (toxic megacolon).

- Warnings and precautions

o You should tell your doctor about the following circumstances before taking Plenvu:

- if you have heart problems and/or arrhythmias;

- if you have kidney problems and/or suffer from dehydration;

- if you have stomach or intestinal problems, including intestinal inflammation;

- if you have difficulty or discomfort when swallowing liquids;

- if you have high or low levels of electrolyte (e.g. sodium, potassium);

- if you have other diseases (e.g. convulsions).

- Pregnancy and lactation o There are no data on the use of Plenvu during pregnancy or lactation and is therefore not recommended.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Plenvu
All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines

Locations

Country Name City State
Germany Dr. Helmut Neumann Bad Salzuflen Northrine-Westfalia
Germany Dr. Horst Hohn Koblenz Rhenanie-Palatinate
Germany University Hospital Mainz Mainz

Sponsors (1)

Lead Sponsor Collaborator
Johannes Gutenberg University Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Boston Bowel Preparation Standard (BBPS) Bowel preparation according to international Standard (1 is bad, 9 is good), how many BBPs with 9 can be achieved? 1 week
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 How good will patients tolerate endoscopy and preparation 1 day
Primary Number of patients with adverse events What Kind of adverse Events can happen during this study up to 1 week
Secondary Number of patients who are willing to accept repeated examination (surveillance); How many patients will come back for another endoscopy up to 1 month
Secondary Adenoma and Polyp Detection Rate (ADR and PDR) How many adenomas and polyps are detected during endoscopy 1 day
Secondary cecal intubation rate how many endoscopies will reach the ceacum 1 day
Secondary procedure time how Long will endoscopy take 3 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1